See more : Sumitomo Rubber Industries, Ltd. (5110.T) Income Statement Analysis – Financial Results
Complete financial analysis of Amryt Pharma plc (AMYT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Amryt Pharma plc, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- A1 Group, Inc. (AWON) Income Statement Analysis – Financial Results
- SBI Leasing Services Co., Ltd. (5834.T) Income Statement Analysis – Financial Results
- X5 Retail Group N.V. (FIVE.IL) Income Statement Analysis – Financial Results
- Terra Balcanica Resources Corp. (TERA.CN) Income Statement Analysis – Financial Results
- The Joint Corp. (JYNT) Income Statement Analysis – Financial Results
Amryt Pharma plc (AMYT)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.amrytpharma.com
About Amryt Pharma plc
Amryt Pharma plc, a commercial-stage biopharmaceutical company, focuses on acquiring, developing, and commercializing various treatments to help improve the lives of patients with rare and orphan diseases. The company provides metreleptin, an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; oral octreotide, a long-term maintenance therapy in acromegaly patients; and lomitapide, an adjunct to a low-fat diet and other lipid-lowering medicinal products for adults with the Homozygous familial Hypercholesteraemia. Its development candidates include Oleogel-S10 for the cutaneous manifestations of Junctional and Dystrophic Epidermolysis Bullosa (EB), a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene therapy for patients with dystrophic EB. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is headquartered in Dublin, Ireland.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 222.54M | 182.61M | 58.12M | 16.53M | 15.33M | 1.42M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 106.12M | 119.03M | 42.00M | 6.06M | 6.45M | 616.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 116.42M | 63.58M | 16.12M | 10.47M | 8.88M | 804.55K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 52.32% | 34.82% | 27.74% | 63.35% | 57.95% | 56.62% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 37.73M | 27.62M | 15.83M | 10.35M | 12.67M | 2.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 8.34M | 4.73M | 841.00K | 17.57M | 13.25M | 4.25M | 3.33M | 2.93M | 1.87M | 275.37K | 281.22K | 1.72M | 1.74M | 3.05M | 2.33M |
| Selling & Marketing | 92.00M | 76.67M | 35.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 100.34M | 81.40M | 36.34M | 17.57M | 13.25M | 4.25M | 3.33M | 2.93M | 1.87M | 275.37K | 281.22K | 1.72M | 1.74M | 3.05M | 2.33M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -80.83K | -47.51K | 5.03K | 11.50K |
| Operating Expenses | 138.07M | 109.02M | 52.17M | 27.92M | 25.93M | 6.95M | 3.34M | 2.93M | 1.86M | 275.37K | 281.22K | 281.82K | 1.74M | 3.05M | 2.33M |
| Cost & Expenses | 244.18M | 228.05M | 94.17M | 33.98M | 32.37M | 7.57M | 3.34M | 2.93M | 1.86M | 275.37K | 281.22K | 281.82K | 1.74M | 3.05M | 2.33M |
| Interest Income | 5.00K | 87.00K | 92.00K | 5.72K | 6.00K | 1.05K | 185.00K | 201.00K | 319.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 27.91M | 19.57M | 8.48M | 1.78M | 989.75K | 127.26K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 50.74M | 44.47M | 12.63M | 354.61K | 310.72K | 204.03K | 6.00K | 6.00K | 4.56K | 0.00 | 99.63K | 147.69K | 144.69K | 224.23K | 161.09K |
| EBITDA | 29.10M | -977.00K | -23.42M | -17.09M | -16.73M | -5.94M | 33.26M | -3.10M | -1.27M | -275.37K | -281.22K | -281.82K | -1.60M | -2.83M | -2.17M |
| EBITDA Ratio | 13.08% | -0.54% | -40.29% | -103.36% | -109.16% | -418.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -21.64M | -45.44M | -36.04M | -17.44M | -17.04M | -8.08M | -39.93M | -2.93M | -3.51M | -275.37K | -281.22K | -281.82K | -459.87K | -3.28M | -2.43M |
| Operating Income Ratio | -9.72% | -24.89% | -62.01% | -105.51% | -111.18% | -568.69% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -8.17M | -60.42M | -30.72M | -12.00M | -14.31M | -127.26K | 189.00K | -36.81M | 376.00K | -1.84M | -5.85K | 0.00 | -63.03K | 7.94K | 14.28K |
| Income Before Tax | -29.81M | -105.86M | -66.76M | -29.45M | -31.36M | -8.21M | -39.74M | -2.56M | -2.12M | -275.37K | -281.22K | -281.82K | -522.90K | -3.27M | -2.41M |
| Income Before Tax Ratio | -13.40% | -57.97% | -114.86% | -178.09% | -204.54% | -577.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -11.64M | -1.33M | -1.23M | 41.18K | 14.31M | 1.93M | 73.18M | -175.00K | 2.23M | 550.74K | 2.68M | 1.51K | -25.79K | 226.22K | 101.27K |
| Net Income | -18.17M | -104.53M | -65.54M | -29.49M | -45.67M | -8.21M | -39.74M | -2.56M | -2.12M | -826.12K | -3.06M | -123.58K | -497.11K | -3.27M | -2.41M |
| Net Income Ratio | -8.17% | -57.24% | -112.75% | -178.34% | -297.89% | -577.65% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.39 | -2.92 | -4.32 | -3.22 | -6.14 | -1.51 | -3.45 | -0.26 | -0.33 | -0.08 | -0.30 | -0.01 | -0.05 | -0.42 | 0.00 |
| EPS Diluted | -0.37 | -2.92 | -4.32 | -3.22 | -6.14 | -1.51 | -3.45 | -0.26 | -0.33 | -0.08 | -0.30 | -0.01 | -0.05 | -0.42 | 0.00 |
| Weighted Avg Shares Out | 47.17M | 35.76M | 15.17M | 9.16M | 7.44M | 5.44M | 11.51M | 9.81M | 6.47M | 10.12M | 10.12M | 10.12M | 9.59M | 7.87M | 0.00 |
| Weighted Avg Shares Out (Dil) | 49.40M | 35.76M | 15.17M | 9.16M | 7.44M | 5.44M | 11.51M | 9.81M | 6.47M | 10.12M | 10.12M | 10.12M | 9.59M | 7.87M | 0.00 |
Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022
Amryt Pharma plc (AMYT) CEO Joseph Wiley on Q2 2022 Results - Earnings Call Transcript
Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q2 Loss, Tops Revenue Estimates
Amryt to Report Q2 2022 Results on August 4, 2022
Amryt (AMYT) Mycapssa Gets Orphan Drug Tag for Carcinoid Syndrome
Amryt Pharma PLC Sponsored ADR (AMYT) Surges 7.5%: Is This an Indication of Further Gains?
Amryt to Present Data from OPTIMAL and MPOWERED Phase 3 Trials Open Label Extension of Mycapssa® (oral octreotide) at ENDO 2022
Amryt Pharma PLC (AMYT) CEO Joseph Wiley on Q1 2022 Results - Earnings Call Transcript
Amryt Pharma PLC Sponsored ADR (AMYT) Reports Q1 Loss, Tops Revenue Estimates
Amryt Shares Trading Higher As EMA Endorses Approval Of Filsuvez In Genetic Skin Disease
Source: https://incomestatements.info
Category: Stock Reports